![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
943kB |
Preview |
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
239kB |
| Item Type: | Article |
|---|---|
| Title: | Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas |
| Creators Name: | Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., Chemnitz, J., Middeke, J.M., Weber, T., Holtick, U., Trappe, R., Pfannes, R., Liersch, R., Spoer, C., Fuxius, S., Gebauer, N., Caillé, L., Geer, T., Koenecke, C., Keller, U., Claus, R., Mougiakakos, D., Mayer, S., Huettmann, A., Pott, C., Trummer, A., Wulf, G., Brunnberg, U., Bullinger, L., Hess, G., Mueller-Tidow, C., Glass, B., Lenz, G., Dreger, P. and Dietrich, S. |
| Abstract: | The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients. |
| Keywords: | Clinical Trials and Observations, Lymphoid Neoplasia, B-Cell Lymphomas, Bendamustine, Chemotherapy Regimen, Chimeric Antigen Receptor T-Cell Therapy, Hematopoietic Stem Cell Transplantation, Lymphoma, Rituximab, Leukapheresis, Antibodies, Chimeric Antigen Receptors |
| Source: | Blood Advances |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Volume: | 5 |
| Number: | 13 |
| Page Range: | 2707-2716 |
| Date: | 13 July 2021 |
| Additional Information: | Copyright © 2021 by The American Society of Hematology |
| Official Publication: | https://doi.org/10.1182/bloodadvances.2020004155 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
